[Access to diagnostic methods for diffuse gliomas in adults in Argentina].

INTRODUCTION

Adult diffuse gliomas require molecular testing for accurate diagnosis and personalized treatment. In Argentina, access to these biomarkers is uneven, influenced by regional, institutional, and health coverage factors.

Objectives

To analyze access to pathological and molecular diagnostic methods for adult diffuse gliomas in Argentina, identifying inequalities and barriers.

METHODS

Observational, descriptive, cross-sectional study based on a structured survey of 52 specialists (oncology, neurosurgery, pathology, radiotherapy) conducted between October–December 2024. Biomarker availability, healthcare coverage, and patient volume were assessed. Chi-square, Fisher, and Cochran-Armitage tests were applied.

RESULTS

The most available biomarkers were IDH1/2 non-canonical mutations and 1p/19q codeletion (67%), followed by ATRX/TP53 (62%) and IDH1 R132H (56%). Less available were EGFR and MGMT (44%), BRAF (40%), CDKN2A (23%), TERTp/H3K27M (14%), and Chr7/Chr10 (<10%). Availability was associated with province, workplace, specialty, and patient load. Patients without insurance reported lower access (mean 2.39/5) compared with those with insurance (3.35/5).

CONCLUSION

Molecular diagnostics for adult diffuse gliomas in Argentina remain limited and uneven, with regional and institutional gaps affecting equity. Strengthening diagnostic infrastructure and public funding is essential to ensure precision oncology.